Tumor Targeting by αvβ3-Integrin-Specific Lipid Nanoparticles Occurs via Phagocyte Hitchhiking

Autor: Yohana C. Toner, Elizabeth L. Fisher, Willem J. M. Mulder, Thomas Reiner, Jordi Ochando, Alexandros Marios Sofias, Carlos Pérez-Medina, Camilla Wolowczyk, Anu E. Meerwaldt, Catharina de Lange Davies, Åsmund Flobak, Mattijs Elschot, Haruki Gonai, Geir Bjørkøy, Mandy M. T. van Leent, Kristin Grendstad, Ulrike Neckmann, Abraham J. P. Teunissen, Georgios Soultanidis, Sjoerd Hak

Publikováno v: Repisalud
Instituto de Salud Carlos III (ISCIII)
ACS nano, 14(7), 7832-7846. American Chemical Society
ACS Nano
ACS Nano, 14(7), 7832-7846. American Chemical Society

Although the first nanomedicine was clinically approved more than two decades ago, nanoparticles' (NP) in vivo behavior is complex and the immune system's role in their application remains elusive. At present, only passive-targeting nanoformulations

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e578b88b57e735ad361f4f0ce57c380c
http://hdl.handle.net/20.500.12105/11059